1310-GMP Expansion & Engineering for Cellular Immunotherapy
Researchers have developed a scalable manufacturing platform for immunotherapy by enabling the long-term expansion of granulocyte-monocyte progenitors (GMPs). By identifying that myeloperoxidase (MPO) inhibition unlocks sustained proliferation, the authors created defined culture conditions to produce vast quantities of these myeloid precursors from both mice and humans. Unlike terminal macrophages, these engineered progenitors engraft in hematopoietic niches, providing a continuous supply of donor-derived immune cells that persist and infiltrate tumors. The study demonstrates that…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.